CNTA Logo

Centessa Pharmaceuticals plc (CNTA) 

NASDAQ
Market Cap
$2.39B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
613 of 966
Rank in Industry
337 of 554

Largest Insider Buys in Sector

CNTA Stock Price History Chart

CNTA Stock Performance

About Centessa Pharmaceuticals plc

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

Insider Activity of Centessa Pharmaceuticals plc

Over the last 12 months, insiders at Centessa Pharmaceuticals plc have bought $0 and sold $11.08M worth of Centessa Pharmaceuticals plc stock.

On average, over the past 5 years, insiders at Centessa Pharmaceuticals plc have bought $75.13M and sold $4.23M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 20,000 shares for transaction amount of $92,568 was made by SAHA SAURABH (Chief Executive Officer) on 2022‑06‑24.

List of Insider Buy and Sell Transactions, Centessa Pharmaceuticals plc

2024-12-06SaleChief Executive Officer
87,496
0.0665%
$18.46$1.62M-1.55%
2024-11-25SaleChief Executive Officer
299
0.0002%
$18.23$5,451+1.73%
2024-11-25SaleChief Business Officer
10,000
0.0079%
$17.66$176,601+1.73%
2024-11-22SaleChief Executive Officer
1,671
0.0015%
$18.24$30,478+1.53%
2024-11-21SaleChief Executive Officer
3,511
0.0027%
$18.24$64,028-5.28%
2024-11-20SaleChief Executive Officer
55,000
0.0424%
$16.89$928,719+3.35%
2024-11-13SaleChief Executive Officer
32,023
0.0284%
$18.28$585,419-5.09%
2024-10-25SaleChief Business Officer
11,742
0.0103%
$15.38$180,6280.00%
2024-10-23SaleChief Executive Officer
2,592
0.0023%
$15.32$39,6970.00%
2024-10-22SaleChief Executive Officer
30,203
0.027%
$15.67$473,1690.00%
2024-10-21SaleChief Executive Officer
22,205
0.0196%
$15.80$350,861+7.50%
2024-09-25SaleChief Business Officer
16,619
0.0148%
$15.69$260,724-0.12%
2024-09-20SaleChief Executive Officer
55,000
0.0484%
$16.53$908,985-2.80%
2024-09-10SaleChief Executive Officer
175,000
0.1752%
$16.52$2.89M+10.70%
2024-09-10SaleChief Business Officer
30,000
0.0309%
$17.00$510,000+10.70%
2024-09-09SaleChief Business Officer
25,000
0.0222%
$15.00$375,000+7.94%
2024-08-23SaleChief Executive Officer
46,651
0.0395%
$12.30$573,905+24.44%
2024-08-23SaleChief Business Officer
17,802
0.015%
$12.29$218,792+24.44%
2024-08-22SaleChief Executive Officer
506
0.0004%
$12.23$6,188+31.07%
2024-08-22SaleChief Business Officer
12,198
0.0107%
$12.17$148,430+31.07%

Insider Historical Profitability

<0.0001%
SAHA SAURABHChief Executive Officer
575661
0.4372%
$18.18315<0.0001%
Weinhoff Gregory MChief Business Officer
183266
0.1392%
$18.1819<0.0001%
Anderson Karen M.Chief People Officer
71525
0.0543%
$18.1801
Rotman HarrisSVP Regulatory Affairs
62625
0.0476%
$18.1802
GAP (Bermuda) LTD10 percent owner
9681818
7.3537%
$18.1810<0.0001%
De Rubertis Francescodirector
3936970
2.9903%
$18.1860<0.0001%
Medicxi Ventures Management (Jersey) Ltd10 percent owner
3936970
2.9903%
$18.1860<0.0001%
GOYAL ARJUNdirector
3825659
2.9057%
$18.1810<0.0001%
GRAINGER DAVID JChief Innovation Officer
908575
0.6901%
$18.1812<0.0001%
YVER ANTOINEEVP & Chairman of Development
783066
0.5948%
$18.18017
CHAO DAVID MChief Administrative Officer
222932
0.1693%
$18.1812<0.0001%
Shahidi JavadChief Medical Officer
158932
0.1207%
$18.1802
HUSSAIN IQBAL JGeneral Counsel
154712
0.1175%
$18.1812<0.0001%
Templeman ThomasChief Technology Officer
135792
0.1031%
$18.1812<0.0001%
KANTOFF AARONdirector
60000
0.0456%
$18.1810<0.0001%
Thorell MarellaChief Accounting Officer
1000
0.0008%
$18.1810<0.0001%
Bush Tia LChief Quality Officer
0
0%
$18.1823<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Medicxi Growth I Lp$225.58M17.6619.96M0%+$050.22
General Atlantic$109.4M8.579.68M0%+$02.84
Ecor1 Capital Llc$63.49M4.975.62M0%+$00.45
Vida Ventures Advisors Llc$44.43M3.483.93M0%+$024.68
Perceptive Advisors$34.84M2.733.08MNew+$34.84M0.02
First Light Asset Management$33.92M2.663MNew+$33.92M2.86
T. Rowe Price$33.43M2.622.96M+16.48%+$4.73M<0.01
Fidelity Investments$31.5M2.472.79M0%+$0<0.01
Point72 Asset Management$25.51M22.26M+22.67%+$4.71M0.04
Adage Capital Partners Gp L L C$25.43M1.992.25M-22.31%-$7.3M0.05
Morgan Stanley$24.15M1.892.14M+76.05%+$10.43M<0.01
Octagon Capital Advisors LP$23.28M1.822.06M0%+$00.13
Tcg Crossover Management Llc$23.06M1.812.04M0%+$00.04
Artal Group S A$15.96M1.251.41M+39.51%+$4.52M0.07
5Am Venture Management Llc$14.07M1.11.25MNew+$14.07M0.95
Franklin Templeton Investments$13.07M1.021.16M+3.67%+$462,237.80<0.01
Driehaus Capital Management LLC$12.48M0.981.1M+281.51%+$9.21M0.12
American Century Investments$10.43M0.82923,120+5.41%+$535,112.060.01
Affinity Asset Advisors$9.39M0.74830,546+4.38%+$393,432.110.14
Tanager Wealth Management$7.87M0.62696,0960%+$01.49
Cormorant Asset Management Lp$6.35M0.5561,6000%+$00.3
PLATINUM INVESTMENT MANAGEMENT LTD$5.48M0.43485,174+27.32%+$1.18M0.07
BlackRock$4.32M0.34382,462+10.45%+$408,958.34<0.0001
ExodusPoint Capital Management, LP$4.29M0.34379,314+27.76%+$931,382.460.05
Farallon Capital$4.19M0.33371,000New+$4.19M0.03
PFM Health Sciences$3.56M0.28314,674New+$3.56M0.1
Millennium Management LLC$3.25M0.25287,393+576.43%+$2.77M<0.01
Balyasny Asset Management Llc$2.88M0.23254,446New+$2.88M0.01
Marshall Wace$2.62M0.21231,565New+$2.62M<0.01
Td Asset Management Inc$2.58M0.2228,644+22.72%+$478,374.16<0.01
Renaissance Technologies$2.47M0.19218,800+17.89%+$375,093.24<0.01
Ensign Peak Advisors Inc$1.41M0.11125,1570%+$0<0.01
The Manufacturers Life Insurance Company$1.22M0.1108,048+71.45%+$508,804.93<0.01
Trexquant Investment LP$1.09M0.0996,531+572.5%+$928,599.840.02
Landscape Capital Management$1.02M0.0890,240New+$1.02M0.08
Two Sigma$890,225.000.0778,781+377.46%+$703,775.06<0.01
Bank of America$869,919.000.0776,984+107.9%+$451,480.10<0.0001
Cubist Systematic Strategies$820,482.000.0672,609+1,405.16%+$765,970.780.01
Prelude Capital$780,932.000.0669,109New+$780,932.000.06
Goldman Sachs$621,805.000.0555,027+122.5%+$342,344.74<0.0001
Citadel Advisors LLC$530,738.000.0446,968-53.41%-$608,346.34<0.0001
Geode Capital Management$378,990.000.0333,5390%+$0<0.0001
Jump Financial Llc$371,465.000.0332,873+129.88%+$209,874.96<0.01
Rathbone Brothers$353,690.000.0331,3000%+$0<0.01
Acadian Asset Management$330,000.000.0329,409New+$330,000.00<0.01
JPMorgan Chase$308,095.000.0227,265+156.49%+$187,975.80<0.0001
Lynx1 Capital Management Lp$196,620.000.0217,400New+$196,620.000.01
Gsa Capital Partners Llp$154,000.000.0113,587New+$154,000.000.01
China Universal Asset Management Co., Ltd.$122,232.000.0110,817+69.17%+$49,979.860.01
Qube Research & Technologies$101,067.000.018,944+582.23%+$86,252.73<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.